CleveXel Pharma is licensing two patents relating to diagnosis and treatment of myelodysplasia and leukaemia.

Satt Sud Est is granting a license for two patents to CleveXel Pharma, a French biotech focused on oncology, diseases of the central nervous system and immuno-inflammation. The patents, one for diagnosis and one for treatment, relate to myelodysplasia and acute myeloid leukaemia.

The diagnostic patent is held by the University Hospital Nice, Nice Sophia Antipolis University and the French Institute of Health and Medical Research. The treatment patent is also held by Nice Sophia Antipolis University and the French…